文献速递妇科

贝伐珠单抗生物类似药治疗复发性铂敏感卵巢癌的成本效果

Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.
PubMed 文献 · Gynecol Oncol · 2026-07-14

该研究基于GOG-0213试验数据,评估贝伐珠单抗生物类似药(bevacizumab-awwb)联合铂类化疗对比单纯化疗治疗复发性铂敏感上皮性卵巢癌的成本效果。结果显示,原研贝伐珠单抗的ICER为399,400美元/生命年,而生物类似药降至131,900美元/生命年,低于150,000美元/生命年的支付意愿阈值。

要点

  • 生物类似药联合化疗的ICER为131,900美元/生命年,低于150,000美元/生命年阈值。
  • 原研贝伐珠单抗联合化疗的ICER为399,400美元/生命年,高于支付意愿阈值。
  • 贝伐珠单抗(或生物类似药)价格需低于27美元/10mg才具成本效果。

核心结论

  • 贝伐珠单抗治疗复发性铂敏感上皮性卵巢癌具有成本效果潜力,前提是其价格与当前最低价生物类似药相近。

研究设计与样本

  • 基于GOG-0213试验的治疗方案和生存估计,比较贝伐珠单抗生物类似药或原研贝伐珠单抗联合铂类化疗与单纯化疗的终身成本和 median overall survival。
  • 成本数据来自Centers for Medicare & Medicaid Services,假设原研贝伐珠单抗与生物类似药仅成本不同(每10mg分别为74美元和24美元)。

主要发现

  • 单纯铂类化疗的总成本为198,440美元,中位生存期为3.11年。
  • 加用原研贝伐珠单抗的总成本为362,206美元,中位生存期为3.52年,ICER为399,400美元/生命年。
  • 使用生物类似药替代原研贝伐珠单抗的总成本为252,512美元,ICER为131,900美元/生命年(对比单纯化疗)。

关键数值与推荐

  • 支付意愿阈值为150,000美元/生命年。
  • 贝伐珠单抗(或生物类似药)价格需低于27美元/10mg才具有成本效果,生物类似药价格在此范围内。

临床怎么用

  • 在复发性铂敏感上皮性卵巢癌中,可优先考虑使用低价贝伐珠单抗生物类似药联合铂类化疗以提升成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While bevacizumab may benefit patients with recurrent, platinum-sensitive epithelial ovarian cancer (EOC), its use is inconsistent. In part, this may be due to its cost. To assess whether a lower-cost biosimilar (bevacizumab-awwb) could be cost-effective, we evaluated the cost-effectiveness of bevacizumab-awwb in combination with platinum-based chemotherapy versus chemotherapy alone in this setting. METHODS: We evaluated the incremental cost-effectiveness of 1) bevacizumab-awwb and 2) brand-name bevacizumab, when used with standard, platinum-based chemotherapy. Lifetime costs and median overall survival were compared to those with chemotherapy alone. Treatment regimens and survival estimates were based on the GOG-0213 trial. Costs were obtained from Centers for Medicare & Medicaid Services data. We assumed brand-name bevacizumab and bevacizumab-awwb, the lowest-price biosimilar, were differentiated by cost only ($74 vs $24 per 10 mg). In threshold analysis, we identified bevacizumab and biosimilar costs that would achieve cost-effectiveness at a willingness-to-pay (WTP) threshold of $150,000 per life-year gained (LYG). RESULTS: Total costs of treatment with platinum-based chemotherapy alone were $198,440; median survival was 3.11 years. Adding brand-name bevacizumab increased total costs and median survival ($362,206, 3.52 years), resulting in an ICER of $399,400/LYG. Substituting bevacizumab-awwb for brand-name bevacizumab reduced total costs and the ICER ($252,512, ICER = $131,900/LYG vs. chemotherapy alone). For bevacizumab (or a biosimilar) to be cost-effective within the above-specified WTP threshold, its price would need to be under $27/10 mg; bevacizumab-awwb is within this range. CONCLUSION: Bevacizumab has the potential to be cost-effective in treating recurrent, platinum-sensitive EOC, provided its cost is similar to current, lowest-cost biosimilars.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Seguin CL, Eckel A, Howard DH, et al. Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States. Gynecol Oncol. 2026. PMID: 42447659. doi:10.1016/j.ygyno.2026.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。